Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00201760 · ClinicalTrials.gov registry record · Phase 2

Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by Kari Kendra.

Completed
Registry status
Phase 2
Development phase
10
Enrollment target
1
Study location

NCT00201760 is a Phase 2 study of Breast Cancer that has completed, run by Kari Kendra. The registered enrollment target is 10 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00201760, a Phase 2 study of Breast Cancer, has completed, sponsored by Kari Kendra.

COMPLETED
Registry status
Phase 2
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This study determines the proportion of metastatic breast cancer patients progression free after 6 months when treated with gemcitabine/ cisplatin/ trastuzumab or gemcitabine/ trastuzumab.

Conditions Studied

Breast Cancer

Interventions

  • DRUG Trastuzumab
  • DRUG Cisplatin
  • DRUG Gemcitabine

Study Locations (1)

Ohio

  • Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2005-02-25
Est. Completion 2009-10-31
Phase Phase 2

Sponsor

Kari Kendra

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00201760

The ClinicalTrials.gov registry entry for NCT00201760 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Kari Kendra, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Trastuzumab is the first listed.

NCT00201760 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00201760 about?

NCT00201760 is a clinical study titled "Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer". This study determines the proportion of metastatic breast cancer patients progression free after 6 months when treated with gemcitabine/ cisplatin/ trastuzumab or gemcitabine/ trastuzumab.

What is the current status of trial NCT00201760?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2005-02-25. Estimated completion is 2009-10-31.

What conditions does trial NCT00201760 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00201760?

The interventions under investigation include: Trastuzumab (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG).

Who is sponsoring clinical trial NCT00201760?

This trial is sponsored by Kari Kendra, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00201760 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.